Skip to search formSkip to main contentSkip to account menu
Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study
View on Elsevier
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
TLDR
Esketamine is expected to address an unmet medical need in this population through its novel mechanism of action and rapid onset of antidepressant efficacy and is supported by the efficacy and safety of esketamine nasal spray as a rapidly acting antidepressant for patients with treatment-resistant depression.
View on PubMed
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial
TLDR
In this first clinical study to date of intranasal esketamine for TRD, antidepressant effect was rapid in onset and dose related and response appeared to persist for more than 2 months with a lower dosing frequency.
View on Wolters Kluwer
A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.
OBJECTIVE Ketamine, an N-methyl-d-aspartate glutamate receptor antagonist, has demonstrated a rapid-onset antidepressant effect in patients with treatment-resistant depression. This study evaluated…
View on PubMed
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
TLDR
Continuation of esketamine nasal spray in addition to oral antidepressant treatment resulted in clinically meaningful superiority in delaying relapse compared with antidepressant plus placebo in patients with TRD in stable remission.
View on PubMed
Health-related quality of life in depression: a STAR*D report.
  • E. Daly, M. Trivedi, A. Rush
  • Psychology, Medicine
    Annals of clinical psychiatry : official journal…
  • 1 February 2010
TLDR
Sociodemographically disadvantaged patients with greater general medical and depressive illness burden are at greatest risk for poorer quality of life, with distinct impairments seen in the 3 domains of HRQOL.
View on PubMed
Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study…
TLDR
The treatment effect (Montgomery-Asberg Depression Rating Scale) for both esketamine/antidepressant groups exceeded what has been considered clinically meaningful for approved antidepressants vs placebo.
View PDF
Barriers to implementation of a computerized decision support system for depression: an observational report on lessons learned in "real world" clinical settings
TLDR
The following narrative report based on observations obtained during the initial testing and use of a CDSS-D in clinical settings further emphasizes the importance of taking into account organizational factors when planning implementation of evidence-based guidelines or decision support within a system.
View on Springer
Increase in work productivity of depressed individuals with improvement in depressive symptom severity.
TLDR
Patients with clinically significant reductions in symptom severity during initial treatment were more likely than nonresponders to experience significant improvements in work productivity, implying a need for additional, possibly novel, treatments.
View on PubMed
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
TLDR
Long-term esketamine nasal spray plus new OAD therapy had a manageable safety profile, and improvements in depression appeared to be sustained in patients with TRD.
View on PubMed
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License